Skip to content

Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda

Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05783375
Acronym
ADUNU
Enrollment
221
Registered
2023-03-24
Start date
2024-05-01
Completion date
2028-01-31
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic Heart Disease

Brief summary

The goal of this prospective study is to evaluate the feasibility, sustainability, and public health impact of a district-based program for secondary prevention of Rheumatic Heart Disease (RHD) in Uganda.

Detailed description

ADUNU is a non-randomized experiment, testing a strategy for implementing an evidence-based practice, decentralized RHD preventive services. The objectives of the study are to: Objective 1: Demonstrate the impact of ADUNU, using the RE-AIM framework to assess program Reach, Effectiveness, Adoption, Implementation and Maintenance. Objective 2: Estimate the cost-effectiveness and budget impact of ADUNU. ADUNU is a public health initiative that will be deployed the Uganda ministry of health in partnership with the District Health Offices (DHO) in two districts. The program will be overseen by the Technical and Quality Assurance (TAQA). ADUNU's main components will include a RHD testing program which consists of community and facility based echocardiographic screening of children and young adults and a registry based secondary prophylaxis injections of Benzathine penicillin G (BPG) at local health centers III and IVs in both districts.

Interventions

OTHERADUNU program for delivery of RHD care services

The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER
Uganda Heart Institute
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* residing in one of two involved districts in Uganda * providers at HCIIIs and HCIVs located in one of two involved Ugandan districts

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Proportion of persons with RHD reached by the ADUNU program5 year endpointThis objective will involve only secondary analysis of de-identified data collected by districts using routine MOH data collection procedures supplemented by some routine program data during the Ministry's rollout of the ADUNU Programme Package. The number of individuals screened and screening positivity rates will be extracted from screening logs implemented and maintained by DHOs and assessed by modality (school fairs, health days, passive health center screening, and active outreach to family members of RHD diagnosed).
Proportion of persons with RHD enrolled in care, retained and adherent to treatment3 monthsSecondary analysis of data from the districts RHD registry will be used to assess the proportion of registrants enrolled, retained and adherent to secondary prophylaxis.
Adoption and implementation of the ADUNU program at the organization level surveysBaselineBrief surveys will be filled out by providers who are acting as administrators of their health centre and will include questions on a range of logistic (e.g., availability of commodities and stockouts, basic infrastructure reliability) and organizational readiness topics (e.g., staffing levels and turnover, organization of patient scheduling, district support visits)
Adoption and implementation of the ADUNU program at the provider level6 monthsTwo types of data collection activities from frontline providers will be used to understand individual provider-level adoption and maintenance over time: provider surveys and in-depth interviews of providers. A standardized survey instrument on Adoption and a standardized checklist on implementation fidelity that will be completed by the research staff via direct observation. Research staff will use a standardized checklist that will be developed from the core elements of RHD testing (e.g., ultrasound technique, saving of images) and secondary prevention (e.g., injection technique, adequate post-injection monitoring for anaphylaxis)
Adoption and implementation of the ADUNU program at the patient level interview24 monthsWe will conduct a limited number of interviews of registry patients in each district stratified by adherence outcomes as well as age group (adult vs children).
Cost-analysis of the ADUNU program3 year endpointTo estimate program costs, we will use the standardized data collection instruments. Our instruments will measure fixed and capital costs, as well as variable or recurrent costs. Ingredients-based costing will be used for drugs and consumables, personnel costs, and equipment costs, whereas gross costing will be used for "indirect" costs such as facility rents and utilities and maintenance. Relevant data for ingredients-based costing include study data on participant healthcare utilization and price lists of drugs, consumables, and equipment. DHO budget sheets for health facilities and overall health service utilization will be used for gross costing. Both financial costs and economic costs will be measured. We will also estimate of out-of-pocket costs borne by registrants, which will allow us to estimate costs from the patient/household perspective.

Countries

Uganda

Contacts

CONTACTNdate Fall
ndate.fall@cchmc.org15135171327
CONTACTMary Banks
mary.Banks@cchmc.org
PRINCIPAL_INVESTIGATORAndrea Z Beaton

Cincinnati Chidren's hospital

PRINCIPAL_INVESTIGATOREmmy H Okello

Uganda Heart Institute

PRINCIPAL_INVESTIGATORDavid Watkins

University of Washington

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026